Novel Coronavirus Pneumonia(COVID-19)
Conditions
Interventions
Experimental group:Conventional treatent and adalimumab
Control group:conventional treatment
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects who meet the following conditions can become subjects of this study: 1. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian; 2. Chinese aged >=18 years; 3. In accordance with NCP criteria for severe and critical illness, namely "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)". Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment. 4. The course of disease is within 14 days after the onset of illness; 5. Will take nasopharyngeal or oropharyngeal swabs before administration.
Exclusion criteria
Exclusion criteria: 1. Patients who are participating in other drug clinical trials; 2. Pregnant or lactating women; 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50; 4. Expected survival is less than 1 week; 5. Patients diagnosed with rheumatic immune related diseases; 6. Take orally anti rejection drugs or immunomodulatory drugs for a long time; 7. Hypersensitive to adalimumab or any excipients; 8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TTCI (Time to Clinical Improvement); | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality;Time for body temperature to return to normal;Time of improvement in respiratory symptoms;Proportion of severe to light;Days in hospital;Duration of non-invasive / invasive ventilation;Frequency of serious adverse events;inflammatory factors; | — |
Countries
China
Contacts
Public ContactHuji Xu
Shanghai Changzheng Hospital
Outcome results
None listed